BACKGROUND: Pneumonia is the leading cause of mortality in young children globally, and factors that affect tissue delivery of oxygen may affect outcomes of pneumonia. We studied whether altitude and anemia influence disease severity and outcomes in young children with World Health Organization-defined severe pneumonia. METHODS: We analyzed data from the SPEAR (Severe Pneumonia Evaluation Antimicrobial Research) study, a World Health Organization- and USAID-sponsored multinational randomized controlled trial of antibiotics for severe pneumonia among children aged 2 to 59 months in resource-poor settings. The trial enrolled 958 children in 8 sites at varying elevations, classified as high (≥ 2000 m) or low (<2000 m) altitude. We compared illness severity and assessed the effect of anemia on treatment outcome at high and low altitudes, adjusting for potential confounders and study site. RESULTS: Children at high altitudes had significantly lower oxygen saturation on presentation, more cyanosis, lower systolic blood pressure, and higher hemoglobin. After adjusting for potential confounders, anemia predicted treatment failure in children living at high altitude (relative risk: 4.07; 95% confidence interval: 2.60-6.38) but not at low altitude (relative risk: 1.12; 95% confidence interval: 0.96-1.30). Children at high altitude took longer to reach normoxemia than did children at lower altitudes (5.25 vs 0.75 days; P < .0001). CONCLUSIONS: Children at high altitude present with more severe disease, and children with anemia at high altitude are at greater risk of poor outcome when being treated for severe pneumonia. Given the high global prevalence of anemia among young children, prevention and treatment of anemia should be a priority in children living at high altitude and could improve outcomes of pneumonia.
RCT Entities:
BACKGROUND:Pneumonia is the leading cause of mortality in young children globally, and factors that affect tissue delivery of oxygen may affect outcomes of pneumonia. We studied whether altitude and anemia influence disease severity and outcomes in young children with World Health Organization-defined severe pneumonia. METHODS: We analyzed data from the SPEAR (Severe Pneumonia Evaluation Antimicrobial Research) study, a World Health Organization- and USAID-sponsored multinational randomized controlled trial of antibiotics for severe pneumonia among children aged 2 to 59 months in resource-poor settings. The trial enrolled 958 children in 8 sites at varying elevations, classified as high (≥ 2000 m) or low (<2000 m) altitude. We compared illness severity and assessed the effect of anemia on treatment outcome at high and low altitudes, adjusting for potential confounders and study site. RESULTS:Children at high altitudes had significantly lower oxygen saturation on presentation, more cyanosis, lower systolic blood pressure, and higher hemoglobin. After adjusting for potential confounders, anemia predicted treatment failure in children living at high altitude (relative risk: 4.07; 95% confidence interval: 2.60-6.38) but not at low altitude (relative risk: 1.12; 95% confidence interval: 0.96-1.30). Children at high altitude took longer to reach normoxemia than did children at lower altitudes (5.25 vs 0.75 days; P < .0001). CONCLUSIONS:Children at high altitude present with more severe disease, and children with anemia at high altitude are at greater risk of poor outcome when being treated for severe pneumonia. Given the high global prevalence of anemia among young children, prevention and treatment of anemia should be a priority in children living at high altitude and could improve outcomes of pneumonia.
Entities:
Keywords:
anemia; high altitude; international child health; pneumonia
Authors: Alaa H Abou-Zeid; Moataz M Abdel-Fattah; Abdul-salam A Al-Shehri; Tamer M Hifnawy; Sir-Alkhatim A Al-Hassan Journal: Saudi Med J Date: 2006-06 Impact factor: 1.484
Authors: Julie A Choudhuri; Lorraine G Ogden; A James Ruttenber; Deborah S K Thomas; James K Todd; Eric A F Simoes Journal: Pediatrics Date: 2006-02 Impact factor: 7.124
Authors: Llorenç Quintó; John J Aponte; Clara Menéndez; Jahit Sacarlal; Pedro Aide; Mateu Espasa; Inacio Mandomando; Caterina Guinovart; Eusebio Macete; Rosmarie Hirt; Honorathy Urassa; Margarita M Navia; Ricardo Thompson; Pedro L Alonso Journal: Trop Med Int Health Date: 2006-08 Impact factor: 2.622
Authors: Aaron M Harris; Fernando Sempértegui; Bertha Estrella; Ximena Narváez; Juan Egas; Mark Woodin; John L Durant; Elena N Naumova; Jeffrey K Griffiths Journal: Environ Health Date: 2011-11-03 Impact factor: 5.984
Authors: Graciela Terán; Washington Cuna; Froilán Brañez; Kristina E M Persson; Martín E Rottenberg; Susanne Nylén; Celeste Rodriguez Journal: Am J Trop Med Hyg Date: 2018-01-01 Impact factor: 2.345
Authors: Brenna M Henn; Laura R Botigué; Carlos D Bustamante; Andrew G Clark; Simon Gravel Journal: Nat Rev Genet Date: 2015-05-12 Impact factor: 53.242
Authors: Dina Goodman; Mary E Crocker; Farhan Pervaiz; Eric D McCollum; Kyle Steenland; Suzanne M Simkovich; Catherine H Miele; Laura L Hammitt; Phabiola Herrera; Heather J Zar; Harry Campbell; Claudio F Lanata; John P McCracken; Lisa M Thompson; Ghislaine Rosa; Miles A Kirby; Sarada Garg; Gurusamy Thangavel; Vijayalakshmi Thanasekaraan; Kalpana Balakrishnan; Carina King; Thomas Clasen; William Checkley Journal: Lancet Respir Med Date: 2019-10-04 Impact factor: 30.700